Clinical Trials Logo

PR-Positive Breast Cancer clinical trials

View clinical trials related to PR-Positive Breast Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04504331 Terminated - Breast Cancer Clinical Trials

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Start date: October 13, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)